Stage-aware quantification of the SARS-CoV-2 3CLpro biomarker via CsPbBr3@COF-LZU1@AuNP electrochemiluminescence and Cas13a amplification.

Radiotherapy in primary central nervous system lymphoma: Evolution of its role and current position in combined treatment strategies.

Pre-eclampsia is a complex multisystem hypertensive disorder of pregnancy and a leading cause of maternal and perinatal morbidity and mortality worldwide. Increasing evidence suggests that the condition extends beyond abnormal placentation and represents an integrated immuno-cardiovascular disorder characterized by immune dysregulation, endothelial dysfunction, thromboinflammation, and cardiovascular maladaptation. This narrative review examines the interconnected mechanisms linking cytokine-mediated inflammation, endothelial injury, coagulation abnormalities, and maternal cardiovascular instability in pre-eclampsia. A structured literature search of major biomedical databases was conducted to identify relevant experimental, clinical, and translational studies addressing inflammatory cytokines, angiogenic imbalance, endothelial dysfunction, thrombosis, biomarkers, and therapeutic strategies in pre-eclampsia. The review highlights the central roles of pro-inflammatory mediators, including tumor necrosis factor-α, interleukin-6, interleukin-17, and interferon-γ, in promoting oxidative stress, vascular inflammation, and endothelial dysfunction. Particular attention is given to the development of an immunothrombotic environment, defined as the pathological interaction between immune activation and coagulation pathways that promotes thrombosis and vascular injury. The review also critically evaluates the contribution of antiangiogenic factors, platelet activation, impaired fibrinolysis, and cardiovascular remodeling to maternal disease progression. In addition, current and emerging therapeutic approaches targeting inflammatory, endothelial, angiogenic, and thrombotic pathways are discussed, together with their translational potential and clinical limitations. By integrating immunological, vascular, hematological, and cardiovascular perspectives, this review provides a comprehensive framework for understanding the pathophysiology of pre-eclampsia and identifies important knowledge gaps for future investigation.

Cepharanthine triggers immunogenic cell death in solid tumors by suppressing protein kinase C zeta-mediated poly(ADP-ribose) polymerase 1 expression and synergizes with immunotherapy.

Targeting pyroptosis in tauopathies: A redox-driven axis of neuroinflammation and neurodegeneration.

Long non-coding RNAs as regulators of immune signaling pathways in esophageal cancer.

Ultrasensitive chemiluminescent detection of plasma Aβ1-40 based on soluble macromolecular signal amplification carrier.

From bench to gut: Translational horizons in probiotic nanoencapsulation for enhanced host-microbiome synergy.

On-demand hydrogen sulfide-releasing hydrogel reprogramming the diabetic wound microenvironment to accelerate healing.

Cell-free fat extract attenuates temporomandibular joint osteoarthritis via repressing ATF3-binding chromatin accessibility.

Honeysuckle-derived vesicle-like nanoparticle and their hybrid vesicle as novel drug delivery systems for glioma therapy.

Visceral leishmaniasis is a vector-mediated parasitic disease caused by Leishmania donovani. Its treatment relies on chemotherapy with limited options. Existing drugs face significant challenges, including low efficacy, high relapse rates, toxicity, and cost. Therefore, exploring novel chemotherapeutic strategies identified as newer drugs targeting L. donovani CYP51 either alone or in combination with Miltefosine, which presents a promising alternative to current therapy. Here, we have evaluated the antileishmanial potential of an azole drug, luliconazole, which was previously demonstrated to target the sterol biosynthesis pathway in Leishmania major, in combination with conventional antileishmanial agents. Luliconazole exhibited significant inhibitory activity against both extracellular and intracellular L. donovani, with half-maximal inhibitory concentrations of 4.67 and 6.24 µM, respectively. Notably, the addition of miltefosine and luliconazole combinations resulted in a synergistic effect, reducing the effective doses by 3.26- and 5.62-fold compared to monotherapy with miltefosine and luliconazole, respectively. Conversely, the combination of luliconazole with Amphotericin B yielded antagonistic effects. A significant increase in nitric oxide by the parasite-infected macrophages after luliconazole treatment underscores its leishmanicidal potential. Evaluation of host cell cytotoxicity, hemolytic assays, and oxidative burst affirmed the safety of luliconazole. This study is limited to in vitro intracellular amastigote. These findings highlight the efficacy of luliconazole, particularly in combination with miltefosine. Further investigations including formulation development and in vivo validation, are needed to assess the translational potential. This is the first study to demonstrate that luliconazole enhances miltefosine efficacy against L. donovani.

From lab to market: Challenges in translating biosensor innovations to benefit agricultural animal health.

Food-derived bioactive peptides in gut-muscle Axis regulation: Potential and challenges from microbiota homeostasis to muscle metabolism remodeling.

Constructing highly bioactive and tough polyurethane bone adhesives by covalently integrating nanohydroxyapatite.

Traditional Chinese medicine targets vascular endothelial growth factor receptor 2 to treat retinal neovascularization.

Cepharanthine-mediated PD-L1 autophagic degradation via regulation of TSPO and RILP boosts anti-lung cancer chemo-immunotherapy efficacy.

VEGF/VEGFR targeting-induced vascular normalization: a key strategy to reverse cold tumor phenotype and potentiate immunotherapy in gynecologic cancers.

Highly stable and selective flexible sweat sensor combined with bioinspired microfluidic chip: Zn-Ni bimetallic MOF-driven noninvasive renal function assessment.

tsRNA-10547 generated by m1A modification-mediated tRNA shearing promotes colorectal cancer metastasis via suppressing CHRNA9.